KR20100020478A - Ｐ2ｙ12 길항제로서의 피롤 유도체 - Google Patents
Ｐ2ｙ12 길항제로서의 피롤 유도체 Download PDFInfo
- Publication number
- KR20100020478A KR20100020478A KR1020097026371A KR20097026371A KR20100020478A KR 20100020478 A KR20100020478 A KR 20100020478A KR 1020097026371 A KR1020097026371 A KR 1020097026371A KR 20097026371 A KR20097026371 A KR 20097026371A KR 20100020478 A KR20100020478 A KR 20100020478A
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- alkylene
- alkyl
- methyl
- pyrrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000005557 antagonist Substances 0.000 title abstract description 8
- 150000003233 pyrroles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 114
- 238000000034 method Methods 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 9
- 208000037803 restenosis Diseases 0.000 claims abstract description 9
- 208000001435 Thromboembolism Diseases 0.000 claims abstract description 6
- -1 biphenylyl Chemical group 0.000 claims description 181
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 75
- 150000003839 salts Chemical class 0.000 claims description 44
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 32
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 31
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 26
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 22
- 208000007536 Thrombosis Diseases 0.000 claims description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 125000004432 carbon atom Chemical group C* 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 14
- 125000004429 atom Chemical group 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- 229910052760 oxygen Chemical group 0.000 claims description 11
- 239000001301 oxygen Chemical group 0.000 claims description 11
- 125000004076 pyridyl group Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 239000011593 sulfur Substances 0.000 claims description 11
- KVGZZAHHUNAVKZ-UHFFFAOYSA-N 1,4-Dioxin Chemical compound O1C=COC=C1 KVGZZAHHUNAVKZ-UHFFFAOYSA-N 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000003386 piperidinyl group Chemical group 0.000 claims description 10
- 229920006395 saturated elastomer Polymers 0.000 claims description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 9
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 9
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 8
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 8
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 239000011737 fluorine Substances 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 8
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 8
- 238000001356 surgical procedure Methods 0.000 claims description 8
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims description 7
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 7
- 208000005189 Embolism Diseases 0.000 claims description 6
- 125000002947 alkylene group Chemical group 0.000 claims description 6
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 230000002792 vascular Effects 0.000 claims description 6
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical compound C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- IMOGKALIAJTGCX-UHFFFAOYSA-N ethyl 3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-1h-pyrrole-2-carboxylate Chemical compound CC1=C(C(=O)OCC)NC(C)=C1C(=O)C(=O)N1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 IMOGKALIAJTGCX-UHFFFAOYSA-N 0.000 claims description 5
- 125000005968 oxazolinyl group Chemical group 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 5
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 claims description 4
- 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 4
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 4
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 claims description 4
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004530 1,2,4-triazinyl group Chemical group N1=NC(=NC=C1)* 0.000 claims description 4
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 claims description 4
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 claims description 4
- 150000004909 1,2-diazepines Chemical class 0.000 claims description 4
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 claims description 4
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 4
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 claims description 4
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-triazine Chemical compound C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003363 1,3,5-triazinyl group Chemical group N1=C(N=CN=C1)* 0.000 claims description 4
- 150000004910 1,3-diazepines Chemical class 0.000 claims description 4
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims description 4
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 claims description 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 4
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 claims description 4
- 150000004911 1,4-diazepines Chemical class 0.000 claims description 4
- 125000005962 1,4-oxazepanyl group Chemical group 0.000 claims description 4
- ITQYXPMCOLYRDK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide 2H-thiopyran Chemical compound C1SC=CC=C1.O=S1(=O)CCNCC1 ITQYXPMCOLYRDK-UHFFFAOYSA-N 0.000 claims description 4
- 125000000183 1,4-thiazinyl group Chemical group S1C(C=NC=C1)* 0.000 claims description 4
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 claims description 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims description 4
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 claims description 4
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 4
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 claims description 4
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 claims description 4
- KGWNRZLPXLBMPS-UHFFFAOYSA-N 2h-1,3-oxazine Chemical compound C1OC=CC=N1 KGWNRZLPXLBMPS-UHFFFAOYSA-N 0.000 claims description 4
- NTYABNDBNKVWOO-UHFFFAOYSA-N 2h-1,3-thiazine Chemical compound C1SC=CC=N1 NTYABNDBNKVWOO-UHFFFAOYSA-N 0.000 claims description 4
- YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 claims description 4
- ZAISDHPZTZIFQF-UHFFFAOYSA-N 2h-1,4-thiazine Chemical compound C1SC=CN=C1 ZAISDHPZTZIFQF-UHFFFAOYSA-N 0.000 claims description 4
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 4
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims description 4
- BWCDLEQTELFBAW-UHFFFAOYSA-N 3h-dioxazole Chemical compound N1OOC=C1 BWCDLEQTELFBAW-UHFFFAOYSA-N 0.000 claims description 4
- WEQPBCSPRXFQQS-UHFFFAOYSA-N 4,5-dihydro-1,2-oxazole Chemical compound C1CC=NO1 WEQPBCSPRXFQQS-UHFFFAOYSA-N 0.000 claims description 4
- GUUULVAMQJLDSY-UHFFFAOYSA-N 4,5-dihydro-1,2-thiazole Chemical compound C1CC=NS1 GUUULVAMQJLDSY-UHFFFAOYSA-N 0.000 claims description 4
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims description 4
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 claims description 4
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 claims description 4
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 4
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims description 4
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 4
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 4
- 125000005602 azabenzimidazolyl group Chemical group 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 4
- 125000004069 aziridinyl group Chemical group 0.000 claims description 4
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000005512 benztetrazolyl group Chemical group 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 4
- 125000004623 carbolinyl group Chemical group 0.000 claims description 4
- 125000002843 carboxylic acid group Chemical group 0.000 claims description 4
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 238000007887 coronary angioplasty Methods 0.000 claims description 4
- 125000002197 cyclohepta-2,4,6-trienyl group Chemical group 0.000 claims description 4
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 claims description 4
- 125000002150 cyclohexa-1,4-dienyl group Chemical group [H]C1=C([H])C([H])(*)C([H])=C([H])C1([H])[H] 0.000 claims description 4
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 4
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 claims description 4
- DIXBSCZRIZDQGC-UHFFFAOYSA-N diaziridine Chemical compound C1NN1 DIXBSCZRIZDQGC-UHFFFAOYSA-N 0.000 claims description 4
- PPSZHCXTGRHULJ-UHFFFAOYSA-N dioxazine Chemical compound O1ON=CC=C1 PPSZHCXTGRHULJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 4
- 125000003838 furazanyl group Chemical group 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 4
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 claims description 4
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 4
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims description 4
- 125000005969 isothiazolinyl group Chemical group 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 4
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims description 4
- 125000003971 isoxazolinyl group Chemical group 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 4
- 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 claims description 4
- OOFGXDQWDNJDIS-UHFFFAOYSA-N oxathiolane Chemical compound C1COSC1 OOFGXDQWDNJDIS-UHFFFAOYSA-N 0.000 claims description 4
- SJGALSBBFTYSBA-UHFFFAOYSA-N oxaziridine Chemical compound C1NO1 SJGALSBBFTYSBA-UHFFFAOYSA-N 0.000 claims description 4
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 4
- 125000002971 oxazolyl group Chemical group 0.000 claims description 4
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 claims description 4
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims description 4
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims description 4
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims description 4
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 4
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 claims description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 4
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 claims description 4
- 125000002755 pyrazolinyl group Chemical group 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 4
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 4
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 claims description 4
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 208000037804 stenosis Diseases 0.000 claims description 4
- 230000036262 stenosis Effects 0.000 claims description 4
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 4
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims description 4
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims description 4
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 4
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 claims description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 4
- 125000002769 thiazolinyl group Chemical group 0.000 claims description 4
- 125000000335 thiazolyl group Chemical group 0.000 claims description 4
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- 210000003462 vein Anatomy 0.000 claims description 4
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 4
- AICIYIDUYNFPRY-UHFFFAOYSA-N 1,3-dihydro-2H-imidazol-2-one Chemical compound O=C1NC=CN1 AICIYIDUYNFPRY-UHFFFAOYSA-N 0.000 claims description 3
- 125000000164 1,3-thiazinyl group Chemical group S1C(N=CC=C1)* 0.000 claims description 3
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 claims description 3
- SNZGLSFRQQENMS-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 SNZGLSFRQQENMS-UHFFFAOYSA-N 0.000 claims description 3
- 206010002388 Angina unstable Diseases 0.000 claims description 3
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 229940122388 Thrombin inhibitor Drugs 0.000 claims description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 208000007814 Unstable Angina Diseases 0.000 claims description 3
- 206010047249 Venous thrombosis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 238000002399 angioplasty Methods 0.000 claims description 3
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 claims description 3
- 125000002619 bicyclic group Chemical group 0.000 claims description 3
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 3
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 3
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims description 3
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 claims description 3
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims description 3
- 125000005438 isoindazolyl group Chemical group 0.000 claims description 3
- 239000003055 low molecular weight heparin Substances 0.000 claims description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 claims description 3
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
- 125000005880 oxathiolanyl group Chemical group 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims description 3
- 239000003868 thrombin inhibitor Substances 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- RPAPVILXKDUTCP-ZHACJKMWSA-N (e)-3-[5-methyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-2-phenyl-1h-pyrrol-3-yl]prop-2-enoic acid Chemical compound CC=1NC(C=2C=CC=CC=2)=C(\C=C\C(O)=O)C=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 RPAPVILXKDUTCP-ZHACJKMWSA-N 0.000 claims description 2
- BMXPSHUHHHRCHU-UHFFFAOYSA-N 3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-1h-pyrrole-2-carboxylic acid Chemical compound N1C(C(O)=O)=C(C)C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1C BMXPSHUHHHRCHU-UHFFFAOYSA-N 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 108010056764 Eptifibatide Proteins 0.000 claims description 2
- 206010022562 Intermittent claudication Diseases 0.000 claims description 2
- 208000034486 Multi-organ failure Diseases 0.000 claims description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 claims description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 206010053648 Vascular occlusion Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000003187 abdominal effect Effects 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
- 229960003886 apixaban Drugs 0.000 claims description 2
- 210000001367 artery Anatomy 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 229960000288 dabigatran etexilate Drugs 0.000 claims description 2
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 229960000610 enoxaparin Drugs 0.000 claims description 2
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 claims description 2
- 238000001631 haemodialysis Methods 0.000 claims description 2
- 230000000322 hemodialysis Effects 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 2
- 210000003127 knee Anatomy 0.000 claims description 2
- 230000007774 longterm Effects 0.000 claims description 2
- 210000003141 lower extremity Anatomy 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims description 2
- LCGMUFXDFRKQSI-VAWYXSNFSA-N methyl (e)-3-[5-methyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-2-phenyl-1h-pyrrol-3-yl]prop-2-enoate Chemical compound COC(=O)\C=C\C1=C(C=2C=CC=CC=2)NC(C)=C1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 LCGMUFXDFRKQSI-VAWYXSNFSA-N 0.000 claims description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 229940107685 reopro Drugs 0.000 claims description 2
- 201000004193 respiratory failure Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 230000002537 thrombolytic effect Effects 0.000 claims description 2
- 208000021331 vascular occlusion disease Diseases 0.000 claims description 2
- 238000007891 venous angioplasty Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- YJTKNYDMVHNTCO-UHFFFAOYSA-N 1-(2,5-dimethyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound N1C(C)=CC(C(=O)C(=O)N2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1C YJTKNYDMVHNTCO-UHFFFAOYSA-N 0.000 claims 1
- NSMZPYYQGUTHHX-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-(4-phenylpiperazin-1-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC=C1 NSMZPYYQGUTHHX-UHFFFAOYSA-N 0.000 claims 1
- ZANCQKJLCMDMJS-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[3-(2-piperidin-1-ylethoxy)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C(C=1)=CC=CC=1OCCN1CCCCC1 ZANCQKJLCMDMJS-UHFFFAOYSA-N 0.000 claims 1
- JPYAZKXPHUUZFF-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperidin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C(F)(F)F)=C1 JPYAZKXPHUUZFF-UHFFFAOYSA-N 0.000 claims 1
- KGDQRWWATJJCBO-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[4-(trifluoromethyl)benzoyl]piperidin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(C(F)(F)F)C=C1 KGDQRWWATJJCBO-UHFFFAOYSA-N 0.000 claims 1
- PZNPBGZQCALNRA-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(C(F)(F)F)C=C1 PZNPBGZQCALNRA-UHFFFAOYSA-N 0.000 claims 1
- FHDJWYGJXAIRJR-UHFFFAOYSA-N 1-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[4-nitro-3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 FHDJWYGJXAIRJR-UHFFFAOYSA-N 0.000 claims 1
- ATZWZPDWFILWFD-UHFFFAOYSA-N 1-(2-methyl-5-pyridin-2-yl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2N=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 ATZWZPDWFILWFD-UHFFFAOYSA-N 0.000 claims 1
- NRJJSRHQJQEYFQ-UHFFFAOYSA-N 1-(2-methyl-5-pyridin-3-yl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=NC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 NRJJSRHQJQEYFQ-UHFFFAOYSA-N 0.000 claims 1
- HOGGFZUTADUSDT-UHFFFAOYSA-N 1-(4-bromo-2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=C(Br)C=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 HOGGFZUTADUSDT-UHFFFAOYSA-N 0.000 claims 1
- DBDSEWXCSGWBDU-UHFFFAOYSA-N 1-[3-methyl-4-(3-methylphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC1CN(C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)CCN1C1=CC=CC(C)=C1 DBDSEWXCSGWBDU-UHFFFAOYSA-N 0.000 claims 1
- ATPALYQUTULJLB-UHFFFAOYSA-N 1-[4-(1h-indol-4-yl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound C=1C(C(=O)C(=O)N2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C(C)NC=1C1=CC=CC=C1 ATPALYQUTULJLB-UHFFFAOYSA-N 0.000 claims 1
- FCYCNLVTOUOJOU-UHFFFAOYSA-N 1-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound C=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C3OCCOC3=CC=2)=C(C)NC=1C1=CC=CC=C1 FCYCNLVTOUOJOU-UHFFFAOYSA-N 0.000 claims 1
- KLPDMVLSUAIIRE-UHFFFAOYSA-N 1-[4-(3,4-dichlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(Cl)C(Cl)=C1 KLPDMVLSUAIIRE-UHFFFAOYSA-N 0.000 claims 1
- HGXCQUWYINPTKV-UHFFFAOYSA-N 1-[4-(3,4-difluorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(F)C(F)=C1 HGXCQUWYINPTKV-UHFFFAOYSA-N 0.000 claims 1
- ZZRFSSQFYYLVQE-UHFFFAOYSA-N 1-[4-(3,5-dichlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC(Cl)=CC(Cl)=C1 ZZRFSSQFYYLVQE-UHFFFAOYSA-N 0.000 claims 1
- BSXGEPMZDLGDBV-UHFFFAOYSA-N 1-[4-(3,5-dimethylphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC(C)=CC(C)=C1 BSXGEPMZDLGDBV-UHFFFAOYSA-N 0.000 claims 1
- QCWURNHNIHKWQS-UHFFFAOYSA-N 1-[4-(3-aminophenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(N)=C1 QCWURNHNIHKWQS-UHFFFAOYSA-N 0.000 claims 1
- REYXRTVYVHRUSJ-UHFFFAOYSA-N 1-[4-(3-bromophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(Br)=C1 REYXRTVYVHRUSJ-UHFFFAOYSA-N 0.000 claims 1
- WANGDVKXSFGBEX-UHFFFAOYSA-N 1-[4-(3-bromophenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(Br)=C1 WANGDVKXSFGBEX-UHFFFAOYSA-N 0.000 claims 1
- YDWGWCQMDBYWIZ-UHFFFAOYSA-N 1-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(F)C(Cl)=C1 YDWGWCQMDBYWIZ-UHFFFAOYSA-N 0.000 claims 1
- DFJIJTKCZUNTRP-UHFFFAOYSA-N 1-[4-(3-chlorobenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=CC(Cl)=C1 DFJIJTKCZUNTRP-UHFFFAOYSA-N 0.000 claims 1
- SUZCLKIKSUNRFV-UHFFFAOYSA-N 1-[4-(3-chlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(Cl)=C1 SUZCLKIKSUNRFV-UHFFFAOYSA-N 0.000 claims 1
- RZYOROIXPABXJU-UHFFFAOYSA-N 1-[4-(3-fluorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(F)=C1 RZYOROIXPABXJU-UHFFFAOYSA-N 0.000 claims 1
- OZGZJMZMOCBDHN-UHFFFAOYSA-N 1-[4-(3-hydroxyphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(O)=C1 OZGZJMZMOCBDHN-UHFFFAOYSA-N 0.000 claims 1
- AXHPSRYFFKKBDH-UHFFFAOYSA-N 1-[4-(3-methoxyphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound COC1=CC=CC(N2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 AXHPSRYFFKKBDH-UHFFFAOYSA-N 0.000 claims 1
- ITQDKALCZQOFMT-UHFFFAOYSA-N 1-[4-(3-methoxyphenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound COC1=CC=CC(C2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 ITQDKALCZQOFMT-UHFFFAOYSA-N 0.000 claims 1
- PKOROYVRKFNWLT-UHFFFAOYSA-N 1-[4-(3-methylbenzoyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C(=O)C1=CC=CC(C)=C1 PKOROYVRKFNWLT-UHFFFAOYSA-N 0.000 claims 1
- VKZFDLIOCMNZHD-UHFFFAOYSA-N 1-[4-(3-methylbenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=CC(C)=C1 VKZFDLIOCMNZHD-UHFFFAOYSA-N 0.000 claims 1
- JPJOKBAVRHNHKE-UHFFFAOYSA-N 1-[4-(3-methylphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(C)=C1 JPJOKBAVRHNHKE-UHFFFAOYSA-N 0.000 claims 1
- FXKUBZWDTLVZHP-UHFFFAOYSA-N 1-[4-(3-methylphenyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C)=C1 FXKUBZWDTLVZHP-UHFFFAOYSA-N 0.000 claims 1
- SSBJSAHRLHDLRN-UHFFFAOYSA-N 1-[4-(4-acetylphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound C1=CC(C(=O)C)=CC=C1N1CCN(C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)CC1 SSBJSAHRLHDLRN-UHFFFAOYSA-N 0.000 claims 1
- KPEUFQPHJQJWCC-UHFFFAOYSA-N 1-[4-(4-bromobenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(Br)C=C1 KPEUFQPHJQJWCC-UHFFFAOYSA-N 0.000 claims 1
- JTQFVVDEFSJZBG-UHFFFAOYSA-N 1-[4-(4-chlorobenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(Cl)C=C1 JTQFVVDEFSJZBG-UHFFFAOYSA-N 0.000 claims 1
- JMNSJPGSDGNTCV-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(Cl)C=C1 JMNSJPGSDGNTCV-UHFFFAOYSA-N 0.000 claims 1
- XOELRIZFIHHDOL-UHFFFAOYSA-N 1-[4-(4-fluorobenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(F)C=C1 XOELRIZFIHHDOL-UHFFFAOYSA-N 0.000 claims 1
- QIGNPMVKKWHDCK-UHFFFAOYSA-N 1-[4-(4-methoxybenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)CC1 QIGNPMVKKWHDCK-UHFFFAOYSA-N 0.000 claims 1
- HEZSUQFWLHJTDL-UHFFFAOYSA-N 1-[4-(4-methoxyphenyl)piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound C1=CC(OC)=CC=C1N1CCN(C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)CC1 HEZSUQFWLHJTDL-UHFFFAOYSA-N 0.000 claims 1
- XEERFRCULMOUHA-UHFFFAOYSA-N 1-[4-(4-methylbenzoyl)piperidin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C(=O)C1=CC=C(C)C=C1 XEERFRCULMOUHA-UHFFFAOYSA-N 0.000 claims 1
- MHUINSPXCFASEY-UHFFFAOYSA-N 1-[4-[(2,4-dichlorophenyl)methyl]piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1CC1=CC=C(Cl)C=C1Cl MHUINSPXCFASEY-UHFFFAOYSA-N 0.000 claims 1
- FGLKLGPHZWIZML-UHFFFAOYSA-N 1-[4-[3,5-bis(trifluoromethyl)phenyl]piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FGLKLGPHZWIZML-UHFFFAOYSA-N 0.000 claims 1
- PKEGELRIKNZESJ-UHFFFAOYSA-N 1-[4-[3-(2-methoxyethoxy)phenyl]piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound COCCOC1=CC=CC(N2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 PKEGELRIKNZESJ-UHFFFAOYSA-N 0.000 claims 1
- DINQHJMSMZPBLE-UHFFFAOYSA-N 1-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)ethane-1,2-dione Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 DINQHJMSMZPBLE-UHFFFAOYSA-N 0.000 claims 1
- FGWFVAFNGRZYAG-UHFFFAOYSA-N 2-[3-[4-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperazin-1-yl]phenoxy]acetamide Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=CC(OCC(N)=O)=C1 FGWFVAFNGRZYAG-UHFFFAOYSA-N 0.000 claims 1
- VSVXBNVVTIBISJ-UHFFFAOYSA-N 2-hydroxyimino-2-(2-methyl-5-phenyl-1H-pyrrol-3-yl)-1-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethanone Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=NO)C(=O)N(CC1)CCN1C1=CC=CC(C(F)(F)F)=C1 VSVXBNVVTIBISJ-UHFFFAOYSA-N 0.000 claims 1
- WXUZKWBVSXIOQP-UHFFFAOYSA-N 3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-n-propyl-1h-pyrrole-2-carboxamide Chemical compound CC1=C(C(=O)NCCC)NC(C)=C1C(=O)C(=O)N1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 WXUZKWBVSXIOQP-UHFFFAOYSA-N 0.000 claims 1
- GCMSLZKMGYSHFQ-UHFFFAOYSA-N 3-[1-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperidin-4-yl]benzoic acid Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C(O)=O)=C1 GCMSLZKMGYSHFQ-UHFFFAOYSA-N 0.000 claims 1
- RHIGGHYFJIMKPU-UHFFFAOYSA-N 3-[1-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperidin-4-yl]benzonitrile Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCC1C1=CC=CC(C#N)=C1 RHIGGHYFJIMKPU-UHFFFAOYSA-N 0.000 claims 1
- AUEQOSYUSYUTHO-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(cyclopropylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C(F)=CC=2)=C(C)NC=1C(=O)NCC1CC1 AUEQOSYUSYUTHO-UHFFFAOYSA-N 0.000 claims 1
- NOGAHADFKFSIRU-UHFFFAOYSA-N 4-[2-[4-(3-chloro-4-fluorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(furan-2-ylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C(F)=CC=2)=C(C)NC=1C(=O)NCC1=CC=CO1 NOGAHADFKFSIRU-UHFFFAOYSA-N 0.000 claims 1
- PRRQVBKOSMOAAX-UHFFFAOYSA-N 4-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(cyclopropylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C=CC=2)=C(C)NC=1C(=O)NCC1CC1 PRRQVBKOSMOAAX-UHFFFAOYSA-N 0.000 claims 1
- TXHVZLJLYTWIMZ-UHFFFAOYSA-N 4-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-(furan-2-ylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C=CC=2)=C(C)NC=1C(=O)NCC1=CC=CO1 TXHVZLJLYTWIMZ-UHFFFAOYSA-N 0.000 claims 1
- RRDYXVDOEWNZMW-UHFFFAOYSA-N 4-[2-[4-(3-chlorophenyl)piperazin-1-yl]-2-oxoacetyl]-n-cyclopropyl-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(Cl)C=CC=2)=C(C)NC=1C(=O)NC1CC1 RRDYXVDOEWNZMW-UHFFFAOYSA-N 0.000 claims 1
- XGZOBGGIKSJSGS-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-oxoacetyl]-3,5-dimethyl-n-(pyridin-3-ylmethyl)-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C(C)NC=1C(=O)NCC1=CC=CN=C1 XGZOBGGIKSJSGS-UHFFFAOYSA-N 0.000 claims 1
- MQNKZNZKEFYWOL-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-oxoacetyl]-3,5-dimethyl-n-propyl-1h-pyrrole-2-carboxamide Chemical compound CC1=C(C(=O)NCCC)NC(C)=C1C(=O)C(=O)N1CCN(C=2C=C(C(Cl)=CC=2)C(F)(F)F)CC1 MQNKZNZKEFYWOL-UHFFFAOYSA-N 0.000 claims 1
- QVEUKZNIASLJJG-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-oxoacetyl]-n-(cyclopropylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C(C)NC=1C(=O)NCC1CC1 QVEUKZNIASLJJG-UHFFFAOYSA-N 0.000 claims 1
- JXFYEBDPEKDIRK-UHFFFAOYSA-N 4-[2-[4-[4-chloro-3-(trifluoromethyl)phenyl]piperazin-1-yl]-2-oxoacetyl]-n-(furan-2-ylmethyl)-3,5-dimethyl-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C(Cl)=CC=2)C(F)(F)F)=C(C)NC=1C(=O)NCC1=CC=CO1 JXFYEBDPEKDIRK-UHFFFAOYSA-N 0.000 claims 1
- IXKDTWNGTBGBPW-UHFFFAOYSA-N 4-[4-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperazin-1-yl]benzonitrile Chemical compound CC=1NC(C=2C=CC=CC=2)=CC=1C(=O)C(=O)N(CC1)CCN1C1=CC=C(C#N)C=C1 IXKDTWNGTBGBPW-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 229960004969 dalteparin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XIJGCBHXJWARSO-UHFFFAOYSA-N ethyl 2-[3-[4-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperazin-1-yl]phenoxy]acetate Chemical compound CCOC(=O)COC1=CC=CC(N2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 XIJGCBHXJWARSO-UHFFFAOYSA-N 0.000 claims 1
- RRPZECHKURCSNV-UHFFFAOYSA-N ethyl 2-[[3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-1h-pyrrole-2-carbonyl]amino]acetate Chemical compound CC1=C(C(=O)NCC(=O)OCC)NC(C)=C1C(=O)C(=O)N1CCN(C=2C=C(C=CC=2)C(F)(F)F)CC1 RRPZECHKURCSNV-UHFFFAOYSA-N 0.000 claims 1
- SYMGZJFJDQPKIF-UHFFFAOYSA-N ethyl 3-[4-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperazin-1-yl]benzoate Chemical compound CCOC(=O)C1=CC=CC(N2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 SYMGZJFJDQPKIF-UHFFFAOYSA-N 0.000 claims 1
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims 1
- 229960001318 fondaparinux Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- FGTYMYKIJLDRDR-UHFFFAOYSA-N methyl 3-[1-[2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetyl]piperidin-4-yl]benzoate Chemical compound COC(=O)C1=CC=CC(C2CCN(CC2)C(=O)C(=O)C2=C(NC(=C2)C=2C=CC=CC=2)C)=C1 FGTYMYKIJLDRDR-UHFFFAOYSA-N 0.000 claims 1
- OWIHJSQJQOUXQW-UHFFFAOYSA-N n-(furan-2-ylmethyl)-3,5-dimethyl-4-[2-oxo-2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]acetyl]-1h-pyrrole-2-carboxamide Chemical compound CC=1C(C(=O)C(=O)N2CCN(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C(C)NC=1C(=O)NCC1=CC=CO1 OWIHJSQJQOUXQW-UHFFFAOYSA-N 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 102100026171 P2Y purinoceptor 12 Human genes 0.000 abstract description 33
- 101710192338 P2Y purinoceptor 12 Proteins 0.000 abstract description 30
- 230000005764 inhibitory process Effects 0.000 abstract description 17
- 230000004913 activation Effects 0.000 abstract description 10
- 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 8
- 239000004480 active ingredient Substances 0.000 abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 4
- 230000006806 disease prevention Effects 0.000 abstract description 4
- 230000002785 anti-thrombosis Effects 0.000 abstract description 3
- 230000001747 exhibiting effect Effects 0.000 abstract description 3
- 230000002429 anti-coagulating effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 230000002441 reversible effect Effects 0.000 abstract description 2
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 23
- 239000000243 solution Substances 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 14
- 210000004623 platelet-rich plasma Anatomy 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000000306 component Substances 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 101001120086 Homo sapiens P2Y purinoceptor 12 Proteins 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- FPQVGDGSRVMNMR-JCTPKUEWSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-(dimethylamino)methylidene]-dimethylazanium;tetrafluoroborate Chemical compound F[B-](F)(F)F.CCOC(=O)C(\C#N)=N/OC(N(C)C)=[N+](C)C FPQVGDGSRVMNMR-JCTPKUEWSA-N 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- ZRBOKMCFDBJZDP-UHFFFAOYSA-N 2-(2-methyl-5-phenyl-1h-pyrrol-3-yl)-2-oxoacetic acid Chemical compound OC(=O)C(=O)C1=C(C)NC(C=2C=CC=CC=2)=C1 ZRBOKMCFDBJZDP-UHFFFAOYSA-N 0.000 description 3
- LOLZVJJIBIGCFD-UHFFFAOYSA-N 2-methyl-5-phenyl-1h-pyrrole Chemical compound N1C(C)=CC=C1C1=CC=CC=C1 LOLZVJJIBIGCFD-UHFFFAOYSA-N 0.000 description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- 235000012501 ammonium carbonate Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000002319 fibrinogen receptor antagonist Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000010118 platelet activation Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- CFRCZLVPCCLZFG-UHFFFAOYSA-N 1,3,4-oxathiazinane 3,3-dioxide Chemical compound O=S1(=O)COCCN1 CFRCZLVPCCLZFG-UHFFFAOYSA-N 0.000 description 2
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical group C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- 0 C*C(C(B(*c1c(C)c(*)c(*)c(*)c1C)C(*)C1C)*)N1C(C(c1c(*)[n](*)c(**)c1*)=*)=O Chemical compound C*C(C(B(*c1c(C)c(*)c(*)c(*)c1C)C(*)C1C)*)N1C(C(c1c(*)[n](*)c(**)c1*)=*)=O 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229940127424 P2Y12 Receptor Antagonists Drugs 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 102000043971 human P2RY12 Human genes 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000018127 platelet degranulation Effects 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- RBLXWIPBPPVLPU-UHFFFAOYSA-N 1-phenylpentane-1,4-dione Chemical compound CC(=O)CCC(=O)C1=CC=CC=C1 RBLXWIPBPPVLPU-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- WNFYMEATYUJKRI-UHFFFAOYSA-N 4-oxo-3h-quinoline-3-carboxamide Chemical class C1=CC=C2C(=O)C(C(=O)N)C=NC2=C1 WNFYMEATYUJKRI-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008092 Cerebral artery thrombosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011084 Coronary artery embolism Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229940122093 Indirect Factor Xa inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000002172 P2Y12 inhibitor Substances 0.000 description 1
- 238000006086 Paal-Knorr synthesis reaction Methods 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010063544 Renal embolism Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000007296 Stetter synthesis reaction Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 1
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- WLMZTKAZJUWXCB-KQYNXXCUSA-N [(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O WLMZTKAZJUWXCB-KQYNXXCUSA-N 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940000279 aggrastat Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002100 cyclohexa-1,3-dienyl group Chemical group [H]C1([*])C([H])=C([H])C([H])=C([H])C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- ALRDOFWBPAZOCW-UHFFFAOYSA-N ethyl 4-acetyl-3,5-dimethyl-1h-pyrrole-2-carboxylate Chemical compound CCOC(=O)C=1NC(C)=C(C(C)=O)C=1C ALRDOFWBPAZOCW-UHFFFAOYSA-N 0.000 description 1
- 238000010228 ex vivo assay Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IRAXRQFCCSHQDX-WBVHZDCISA-N methyl (2s)-2-(butoxycarbonylamino)-3-[[2-[(5r)-3-(4-carbamimidoylphenyl)-4,5-dihydro-1,2-oxazol-5-yl]acetyl]amino]propanoate Chemical compound O1[C@@H](CC(=O)NC[C@H](NC(=O)OCCCC)C(=O)OC)CC(C=2C=CC(=CC=2)C(N)=N)=N1 IRAXRQFCCSHQDX-WBVHZDCISA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000000719 purinergic P2Y receptor antagonist Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010451 regulation of platelet aggregation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229950002267 roxifiban Drugs 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000012622 synthetic inhibitor Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical compound C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical compound C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- DYNGCIHMNWOBSU-MSQVLRTGSA-K trisodium;[[(2r,3s,4r,5r)-5-(6-amino-2-methylsulfanylpurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].C12=NC(SC)=NC(N)=C2N=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O DYNGCIHMNWOBSU-MSQVLRTGSA-K 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07290755 | 2007-06-18 | ||
| EP07290755.3 | 2007-06-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100020478A true KR20100020478A (ko) | 2010-02-22 |
Family
ID=39092503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097026371A Ceased KR20100020478A (ko) | 2007-06-18 | 2008-06-04 | Ｐ2ｙ12 길항제로서의 피롤 유도체 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7910576B2 (https=) |
| EP (1) | EP2167487B1 (https=) |
| JP (1) | JP5371969B2 (https=) |
| KR (1) | KR20100020478A (https=) |
| CN (1) | CN101679358B (https=) |
| AU (1) | AU2008266515B2 (https=) |
| BR (1) | BRPI0812912A2 (https=) |
| CA (1) | CA2690243A1 (https=) |
| IL (1) | IL202758A (https=) |
| MX (1) | MX2009013431A (https=) |
| MY (1) | MY148901A (https=) |
| WO (1) | WO2008155022A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090073231A (ko) | 2006-10-20 | 2009-07-02 | 노파르티스 아게 | ３-(１ｈ-인돌-３-일)-４-[２-(４-메틸-피페라진-１-일)-퀴나졸린-４-일]-피롤-２,５-디온의 결정 변체 |
| WO2013033178A1 (en) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN121108187A (zh) | 2019-04-03 | 2025-12-12 | 阿里戈斯治疗公司 | 吡咯化合物 |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3458515A (en) * | 1966-07-21 | 1969-07-29 | American Home Prod | Piperazine substituted pyrroles |
| US20020061892A1 (en) * | 2000-02-22 | 2002-05-23 | Tao Wang | Antiviral azaindole derivatives |
| US6861424B2 (en) | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
| US6956040B2 (en) * | 2001-07-16 | 2005-10-18 | Ranbaxy Laboratories Limited | Oxazolidinone piperazinyl derivatives as potential antimicrobials |
| OA12970A (en) | 2002-12-11 | 2006-10-13 | Schering Ag | 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists. |
| WO2005009971A1 (ja) | 2003-07-24 | 2005-02-03 | Astellas Pharma Inc. | キノロン誘導体又はその塩 |
| US7273881B2 (en) * | 2004-01-16 | 2007-09-25 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| CN1778801A (zh) * | 2004-11-22 | 2006-05-31 | 中国农业科学院兰州畜牧与兽药研究所 | 喹诺酮7－((4－((z)－2－(2－氨基－4－噻唑基)－2－甲氧亚胺乙酰基)－1－哌嗪基)化合物及其制备方法 |
| EP1836189A1 (en) * | 2005-01-06 | 2007-09-26 | AstraZeneca AB | Novel pyridine compounds |
| JP2008094720A (ja) | 2005-01-20 | 2008-04-24 | Astellas Pharma Inc | キノロン誘導体のプロドラッグ又はその塩 |
| CA2603041A1 (en) * | 2005-03-28 | 2006-10-05 | Pharmacia & Upjohn Company Llc | 4-piperazinylthieno [2, 3-d] pyrimidine compounds as platelet aggregation inhibitors |
| KR101423483B1 (ko) * | 2005-11-03 | 2014-07-28 | 포톨라 파마슈티컬스, 인코포레이티드 | 〔４-(６-할로-７-치환된-２,４-디옥소-１,４-디히드로-２ｈ-퀴나졸린-３-일)-페닐〕-５-클로로티오펜-２-일-설포닐우레아 및 이의 형태 및 이와 관련된 방법 |
| WO2007103456A2 (en) * | 2006-03-06 | 2007-09-13 | Trimeris, Inc. | Piperazine and piperidine biaryl derivatives |
-
2008
- 2008-06-04 CN CN2008800208356A patent/CN101679358B/zh not_active Expired - Fee Related
- 2008-06-04 CA CA2690243A patent/CA2690243A1/en not_active Abandoned
- 2008-06-04 MX MX2009013431A patent/MX2009013431A/es active IP Right Grant
- 2008-06-04 KR KR1020097026371A patent/KR20100020478A/ko not_active Ceased
- 2008-06-04 BR BRPI0812912-6A2A patent/BRPI0812912A2/pt not_active IP Right Cessation
- 2008-06-04 JP JP2010512555A patent/JP5371969B2/ja not_active Expired - Fee Related
- 2008-06-04 EP EP08759015.4A patent/EP2167487B1/en not_active Withdrawn - After Issue
- 2008-06-04 WO PCT/EP2008/004459 patent/WO2008155022A1/en not_active Ceased
- 2008-06-04 AU AU2008266515A patent/AU2008266515B2/en not_active Ceased
- 2008-06-04 MY MYPI20094985A patent/MY148901A/en unknown
-
2009
- 2009-12-15 IL IL202758A patent/IL202758A/en not_active IP Right Cessation
- 2009-12-16 US US12/639,500 patent/US7910576B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101679358A (zh) | 2010-03-24 |
| AU2008266515B2 (en) | 2014-05-01 |
| US7910576B2 (en) | 2011-03-22 |
| CN101679358B (zh) | 2013-10-30 |
| CA2690243A1 (en) | 2008-12-24 |
| JP5371969B2 (ja) | 2013-12-18 |
| JP2010530380A (ja) | 2010-09-09 |
| MY148901A (en) | 2013-06-14 |
| EP2167487A1 (en) | 2010-03-31 |
| IL202758A (en) | 2013-09-30 |
| AU2008266515A1 (en) | 2008-12-24 |
| WO2008155022A1 (en) | 2008-12-24 |
| MX2009013431A (es) | 2010-01-15 |
| HK1142593A1 (en) | 2010-12-10 |
| BRPI0812912A2 (pt) | 2014-12-09 |
| US20100226918A1 (en) | 2010-09-09 |
| IL202758A0 (en) | 2010-06-30 |
| EP2167487B1 (en) | 2015-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5560202B2 (ja) | Ｐ２ｙ１２拮抗薬としてのピラゾール−カルボキサミド誘導体 | |
| JP4861306B2 (ja) | Ｘａ因子阻害剤としてのピロール誘導体 | |
| JP2011527677A (ja) | Ｎｈｅ−１阻害剤として有用なピロリジニル及びピペリジニル化合物 | |
| HRP20010515A2 (en) | 4-(heterocyclylsulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists | |
| JP4939401B2 (ja) | ＴＡＦＩａ阻害剤として用いるイミダゾール誘導体 | |
| JP5371969B2 (ja) | Ｐ２ｙ１２拮抗薬としてのピロール誘導体 | |
| JP4608495B2 (ja) | 第Ｘａ因子阻害剤としてのトリアゾール誘導体 | |
| EP3077380B1 (en) | Thienomethylpiperazine derivatives as inhibitors of soluble epoxide hydrolase | |
| JP5422569B2 (ja) | 凝固第Ｘａ因子及びトロンビンの阻害剤としてのクロロチオフェン−イソオキサゾール類 | |
| US5602149A (en) | 1-OXO-2-(phenylsulphonylamino)pentypiperidine derivatives, their preparation and their therapeutic application | |
| HK1142593B (en) | Pyrrole derivatives as p2y12 antagonists | |
| KR20060012636A (ko) | 인자 Ｘａ 억제제로서의 아자인돌 유도체 | |
| KR101373533B1 (ko) | 인자 Ｘａ 억제제로서의 헤테로아릴-카복실산(설파모일 알킬)아미드 유도체 | |
| KR20060136457A (ko) | 인자 Ｘａ 억제제로서의 피롤-유도체 | |
| MXPA06008712A (en) | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20091217 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20130603 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20141201 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20150601 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20141201 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |